Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: A review of the literature and a meta-analysis

Arthritis Care and Research

Volumn 65, Issue 8, 2013, Pages 1316-1324

  Chen, Zhiyong ^a   Cao, Mengshu ^a   Plana, Maria Nieves ^b   Liang, Jun ^a   Cai, Hourong ^a   Kuwana, Masataka ^c   Sun, Lingyun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CHINESE; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; YOUNG ADULT;

EID: 84881323888     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21985     Document Type: Article

References (38)

1. Mammen AL,. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
2. Sato S, Kuwana M,. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010; 22: 639-43.
3. Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26: 1647-54.
4. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL,. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231-49.
5. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.
6. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.
7. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-40.
8. Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38: 263-7.
9. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49: 1713-9.
10. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
11. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
12. Sontheimer RD,. Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 2010; 146: 76-80.
13. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis. Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
14. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z,. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38: 973-9.
15. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH,. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90.
16. Deeks JJ, Macaskill P, Irwig L,. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-93.
17. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A,. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31-42.
18. Harbord RM,. METANDI: Stata module to perform meta-analysis of diagnostic accuracy. Boston: Statistical Software Components, Boston College Department of Economics; 2008.
19. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T,. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.
20. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 2011; 21: 223-7.
21. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011; 105: 1380-7.
22. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147: 391-8.
23. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T,. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011; 158: 675-7.
24. Sato S, Kuwana M, Fujita T, Suzuki Y,. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 2012; 22: 625-9.
25. Sakurai N, Nagai K, Tsutsumi H, Ichimiya S,. Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement [letter]. J Rheumatol 2011; 38: 963-4.
26. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K,. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011; 13: R214.
27. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51: 1563-70.
28. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
29. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
30. Chen F, Wang D, Shu X, Nakashima R, Wang G,. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32: 3909-15.
31. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-association gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64: 1602-10.
32. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341-7.
33. Horai Y, Isomoto E, Koga T, Okada A, Kawashiri SY, Tamai M, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 2013; 23: 190-4.
34. Sato S, Kuwana M, Fujita T, Suzuki Y,. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2012. E-pub ahead of print.
35. Muro Y, Sugiura K, Hoshino K, Akiyama M,. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012; 51: 800-4.
36. Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8: R13.
37. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD,. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996; 39: 1507-18.
38. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64: 3736-40.